E2 fusion protein and its encoding gene and application
By developing the E2 fusion protein and its encoding gene, and using podophyllotoxin to screen anti-HPV drugs, the problem of the lack of highly efficient and specific anti-HPV drugs in the existing technology has been solved, and efficient screening and target verification of anti-HPV drugs have been achieved.
CN118895263BActive Publication Date: 2026-06-02BEIJING UNIV OF CHEM TECH
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- BEIJING UNIV OF CHEM TECH
- Filing Date
- 2024-09-19
- Publication Date
- 2026-06-02
Smart Images
Figure HDA0005049786520000011 
Figure HDA0005049786520000012 
Figure HDA0005049786520000021
Abstract
The application discloses an E2 fusion protein, a coding gene thereof and application of the E2 fusion protein. The E2 fusion protein is fused by an E2 protein and a label; the amino acid sequence of the E2 protein is shown as positions 1 to 365 from the N-terminal end in SEQ ID NO:1. Experiments prove that the E2 protein has a helicase activity, and an anti-human papillomavirus drug, a podophyllotoxin, can inhibit the helicase activity of the E2 protein. Therefore, the E2 protein is a target of the action of the podophyllotoxin, and the E2 protein can also be used as a target for screening the anti-human papillomavirus drug. The application has important application value in the process of screening the anti-human papillomavirus drug.
Need to check novelty before this filing date? Find Prior Art